Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
05 janv. 2023 02h37 HE
|
Sosei Group Corporation
TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero BioPhase 1...
Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
20 déc. 2022 19h01 HE
|
Sosei Group Corporation
PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10...
Sosei Heptares to present at 41st Annual J.P. Morgan Healthcare Conference
20 déc. 2022 01h30 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill will present at the 41st...
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
15 déc. 2022 19h01 HE
|
Sosei Group Corporation
New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible...
Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders
08 déc. 2022 01h30 HE
|
Sosei Group Corporation
Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant...
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2022
11 nov. 2022 01h30 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2022
09 nov. 2022 03h00 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill and Matt Barnes, Head of UK...
Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
27 oct. 2022 19h05 HE
|
Sosei Group Corporation
NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist TOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”;...
Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum
27 sept. 2022 02h30 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The...
Sosei Heptares Wins Licensing Deal of the Year and Executive of the Year at the Inaugural Informa Pharma Intelligence Awards Japan
01 sept. 2022 19h05 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in...